JP2023554119A5 - - Google Patents

Info

Publication number
JP2023554119A5
JP2023554119A5 JP2023537488A JP2023537488A JP2023554119A5 JP 2023554119 A5 JP2023554119 A5 JP 2023554119A5 JP 2023537488 A JP2023537488 A JP 2023537488A JP 2023537488 A JP2023537488 A JP 2023537488A JP 2023554119 A5 JP2023554119 A5 JP 2023554119A5
Authority
JP
Japan
Prior art keywords
cysteine residue
amino acid
disulfide bond
residue substituent
substituent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023537488A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023554119A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2021/051855 external-priority patent/WO2022133592A1/en
Publication of JP2023554119A publication Critical patent/JP2023554119A/ja
Publication of JP2023554119A5 publication Critical patent/JP2023554119A5/ja
Pending legal-status Critical Current

Links

JP2023537488A 2020-12-21 2021-12-21 安定化されたtcrコンストラクト及び使用方法 Pending JP2023554119A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063128601P 2020-12-21 2020-12-21
US63/128,601 2020-12-21
PCT/CA2021/051855 WO2022133592A1 (en) 2020-12-21 2021-12-21 Stabilized tcr constructs and methods of use

Publications (2)

Publication Number Publication Date
JP2023554119A JP2023554119A (ja) 2023-12-26
JP2023554119A5 true JP2023554119A5 (cg-RX-API-DMAC7.html) 2025-01-06

Family

ID=82157307

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023537488A Pending JP2023554119A (ja) 2020-12-21 2021-12-21 安定化されたtcrコンストラクト及び使用方法

Country Status (8)

Country Link
US (1) US20240409604A9 (cg-RX-API-DMAC7.html)
EP (1) EP4263593A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023554119A (cg-RX-API-DMAC7.html)
KR (1) KR20230123474A (cg-RX-API-DMAC7.html)
CN (1) CN116648256A (cg-RX-API-DMAC7.html)
AU (1) AU2021408160A1 (cg-RX-API-DMAC7.html)
CA (1) CA3167637A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022133592A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190016802A1 (en) 2017-07-14 2019-01-17 Immatics Biotechnologies Gmbh Dual specificity polypeptide molecule
WO2022233956A1 (en) 2021-05-05 2022-11-10 Immatics Biotechnologies Gmbh Antigen binding proteins specifically binding prame
WO2025087436A1 (zh) * 2023-10-27 2025-05-01 北京可瑞生物科技有限公司 基于t细胞受体的多特异性多肽分子及其组合物和用途
TW202542204A (zh) * 2023-12-29 2025-11-01 大陸商上海岸邁生物科技有限公司 融合蛋白及其用途
CN118108833B (zh) * 2024-03-12 2025-05-02 缇纱(合肥)生物技术有限公司 引入外源二硫键的tcr恒定区及其产品和应用
WO2025214470A1 (zh) * 2024-04-12 2025-10-16 江苏恒瑞医药股份有限公司 包含t细胞受体恒定区的蛋白质及其医药用途
WO2025224084A1 (en) 2024-04-22 2025-10-30 Engimmune Therapeutics Ag Proteins comprising t cell receptor constant domains

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190062505A (ko) * 2016-10-03 2019-06-05 주노 쎄러퓨티크스 인코퍼레이티드 Hpv-특이적 결합 분자
CN117843810A (zh) * 2017-09-22 2024-04-09 上海药明生物技术有限公司 新型双特异性多肽复合物
CN109535257B (zh) * 2017-09-22 2021-05-28 同润生物医药(上海)有限公司 新型双特异性cd3/cd19多肽复合物
US11952408B2 (en) * 2017-10-03 2024-04-09 Juno Therapeutics, Inc. HPV-specific binding molecules
CN112585277A (zh) * 2018-04-05 2021-03-30 朱诺治疗学股份有限公司 表达重组受体的t细胞、相关多核苷酸和方法
CN112566698A (zh) * 2018-04-05 2021-03-26 朱诺治疗学股份有限公司 T细胞受体和表达该t细胞受体的工程化细胞

Similar Documents

Publication Publication Date Title
US20240067757A1 (en) COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc CONSTRUCTS
JP7847584B2 (ja) 免疫細胞機能をモジュレートするためのcd8抗原結合分子を有する融合物
AU2015357053B2 (en) Domain-exchanged antibody
ES3008567T3 (en) Recombinant antibody molecule and its use for target cell restricted t cell activation
EP2794658B1 (en) Bispecific antibody molecule
JP7853916B2 (ja) 免疫複合体
JP2020511949A5 (cg-RX-API-DMAC7.html)
CN110914308A (zh) 改进的双特异性多肽分子
CN112424230A (zh) 双功能结合多肽
WO1993011162A1 (en) Bispecific antibody heterodimers
KR20190129896A (ko) Tgf-β-수용체 엑토도메인 융합 분자 및 그의 용도
WO2022125694A1 (en) Fusions of interleukin polypeptides with bispecific antigen binding molecules for modulating immune cell function
JPH05500068A (ja) 可溶性一本鎖t細胞レセプター
US20260132178A1 (en) Engineered immunocytokines, fusion polypeptides, and il10 polypeptides
JP2024526080A (ja) インターロイキン15多様体
WO2023222035A1 (zh) 抗tigit抗体与il2的融合蛋白或其变体及其应用
JP2010512154A (ja) 修飾Fcドメインを含む多量体Fc受容体ポリペプチド
CN101611052A (zh) 包含修饰的Fc结构域的多聚Fc受体多肽
CN120112558A (zh) 治疗慢性病毒感染的含cd8抗原结合分子的融合物
JP2024517658A (ja) 1型真性糖尿病(t1d)を治療するためのmhcクラスii t細胞調節ポリペプチド及びその使用方法
KR20220061644A (ko) Pd-l1 및 il-10의 융합단백질을 유효성분으로 하는 이식거부반응 치료용 약학적 조성물
RU2025135483A (ru) Рекомбинантный слитый белок для лечения легочной гипертензии
JP3844519B2 (ja) 免疫抑制剤
NZ782268A (en) Fusion polypeptide comprising fc region of immunoglobulin and gdf15